[Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].

Abstract

Based on the improved insight into the mechanism of blood coagulation in vivo, recombinant factor VIIa (rFVIIa) has been developed as a pro-haemostatic agent. It has been shown that this treatment is effective in patients with haemophilia and an inhibiting antibody against a coagulation factor. Administration of rFVIIa can be effective in the treatment of bleeding episodes and the prevention of perioperative blood loss in a number of other coagulation disorders as well. Initial clinical studies indicate that administration of rFVIIa may also reduce blood loss in patients with severe bleeding without pre-existent abnormalities in blood coagulation, but this requires confirmation in additional clinical trials.

• Authors: M Levi, Ph W Friederich, J van der Meer
• Journal: Nederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 146 Issue 52 Pg. 2534-7 (Dec 28 2002) ISSN: 0028-2162 [Print] Netherlands
• Vernacular Title: Behandeling en preventie van bloedingen met recombinant-geactiveerde-factor VII, niet alleen bij hemofilie.
• PMID: 12532665 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Autoantibodies
• Recombinant Proteins
• Factor VIIa

Topics

• Autoantibodies (immunology)
• Blood Loss, Surgical (prevention & control)
• Factor VIIa (immunology, therapeutic use)
• Hemophilia A (complications, drug therapy)
• Hemorrhage (drug therapy, etiology)
• Humans
• Recombinant Proteins (therapeutic use)